3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rare Diseases
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Multiple Myeloma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Hypertension, Portal
1
Hepatitis C
1
Fibrosis
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
tremelimumab
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Muscle-invasive Bladder Cancer
×
tremelimumab
×
Clear all
NCT03234153
2020-06-17
NITIMIB
Insel Gruppe AG, University Hospital Bern
Phase 2
Terminated
6 enrolled